Kancera To Pursue Ex-AZ Asset Targeting Fractalkine Into Clinic
Swedish drug developer Kancera has exercised an exclusive option to develop a former AstraZeneca drug candidate. The small molecule shares a mechanism of action with a clinical-stage therapeutic antibody from Eisai.
You may also be interested in...
Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.
Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.